Abstract Number: 1206 • ACR/ARHP Annual Meeting 2017
Chondroitin Sulfate Reduces Pain and Improves Function in Knee Osteoarthritis Significantly Better Than Placebo, Independently of the Definition of Responders
Background/Purpose: In addition to the assessment of the two co-primary endpoints – pain and function – regulatory agencies recommend the use of responder rates in…Abstract Number: 2354 • ACR/ARHP Annual Meeting 2016
Pharmaceutical Grade Chondroitin Sulfate Improves Knee Osteoarthritis Symptoms More Than Placebo and As Much As Celecoxib: Results of the Chondroitin Vs Celecoxib Vs Placebo Trial (CONCEPT)
Background/Purpose: For the assessment of Symptomatic Slow Acting Drugs in Osteoarthritis (SYSADOAs), regulatory Agencies request the assessment of two co-primary endpoints: pain and function. They…
ACR Meeting Abstracts